Literature DB >> 10405364

Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.

M H Skiadopoulos1, S R Surman, M St Claire, W R Elkins, P L Collins, B R Murphy.   

Abstract

A phenylalanine to leucine mutation at position 521 in the L polymerase of cpts530, a live-attenuated respiratory syncytial virus (RSV) cold-passaged (cp), temperature-sensitive (ts) candidate vaccine, specifies the ts and attenuation (att) phenotypes. Sequence alignment of this region in the L proteins of several distantly related paramyxoviruses revealed that this phenylalanine is conserved. Using reverse genetics, the analogous phenylalanine at position 456 in the L protein of wild-type PIV3 was mutagenized to leucine (F456L). The resulting virus, designated r456(L), was ts (40 degrees C shut-off temperature of plaque formation), and its replication in the upper, but not the lower, respiratory tract of hamsters was 10-fold reduced compared with that of the recombinant wild-type PIV3 (rwt). Thus the phenylalanine to leucine mutation specified a similar level of temperature sensitivity and attenuation in two distantly related paramyxoviruses. We next sought to determine whether the addition of this mutation to the L protein of two rPIV3 candidate vaccine viruses, one bearing the three cp45 ts missense mutations in the L protein (rcp45(L)) and the other bearing all 15 cp45 mutations (rcp45), would further attenuate the viruses in vivo. Each rcp45 derivative to which the F456L mutation was added exhibited an increased level of temperature sensitivity. Furthermore rcp45(L)-456 and rcp45-456 were 100- to 1000-fold more restricted in replication in hamsters than their rcp45(L) and rcp45 parents. Despite the high level of restriction of replication in hamsters, immunization with rcp45-456 induced a moderate level of resistance to replication of PIV3 challenge virus. In contrast to the highly restricted replication observed in hamsters, rcp45-456 was only fivefold more restricted in the respiratory tract of chimpanzees than rcp45 and induced a comparable, moderate to high level of PIV3-specific serum antibodies. rcp45 and rcp45-456 viruses isolated from chimpanzees throughout the 2-week course of replication maintained the level of temperature sensitivity of their respective input viruses, illustrating their phenotypic stability. Thus the acquisition of the F456L mutation by the cp45 virus resulted in a small, incremental increase in its level of attenuation, indicating its possible usefulness in the fine tuning of the level of attenuation of the cp45 vaccine candidate. The ability to transfer mutations identified in heterologous paramyxoviruses, which in this case represent different subfamilies, greatly enhances our ability to rapidly develop novel parainfluenza virus candidate vaccines. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405364     DOI: 10.1006/viro.1999.9802

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

Review 1.  Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

Authors:  Brian R Murphy; Peter L Collins
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.

Authors:  Kathryn A Hanley; Jay J Lee; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Josephine McAuliffe; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

5.  The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.

Authors:  Mario H Skiadopoulos; Leatrice Vogel; Jeffrey M Riggs; Sonja R Surman; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.

Authors:  Jason T Newman; Sonja R Surman; Jeffrey M Riggs; Chris T Hansen; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  Virus Genes       Date:  2002       Impact factor: 2.332

7.  Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.

Authors:  T Tao; M H Skiadopoulos; F Davoodi; J M Riggs; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.

Authors:  M H Skiadopoulos; S R Surman; J M Riggs; P L Collins; B R Murphy
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Authors:  Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt
Journal:  Vaccine       Date:  2007-07-03       Impact factor: 3.641

10.  Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Authors:  Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.